Cytomegalovirus End-Organ Disease after Allogenic Hematopoietic Cell Transplant: Descriptive and Comparative Analysis in the Era of Letermovir Prophylaxis (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #762; 569; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "HCT recipients are still at risk for CMV EOD although the incidence decreased with LTV primary prophylaxis. Across all EOD cases, mortality was significantly higher in patients with pneumonitis compared to GI disease. HCT patients who received LTV for primary prophylaxis had more often CMV EOD after day 100 post-transplant but with trends towards lower ACM and NRM at 24 or 48 weeks post- transplant."
Bone Marrow Transplantation • Cytomegalovirus Infection • Gastrointestinal Disorder • Inflammation • Pneumonia • Transplantation
|
|
Tal Schlaeffer- Yosef, MD 1; Fareed Khawaja, MD 2; Tali Shafat, MD 2; Terri Lynn Shigle, PharmD, BCOP 3; Marilyne Daher, MD 2; Vielka Lopez, _ 4; Gabriela Rondon, MD 5; Elizabeth J. Shpall, MD 5; Richard E. Champlin, MD 5; Ella Ariza Heredia, MD 2; Amy Spallone, MD 6; Guy Handley, MD, FACP 2; Roy F. Chemaly, MD, MPH, FIDSA, FACP 7
|